A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signaling pathway as a “door opener” and delivers an additional metabolic modulator specifically into the target cells. In laboratory experiments, mice subsequently ate less, lost more weight, and showed improved blood-glucose values compared with reference treatments. The researchers published their preclinical results in the journal Nature.
This article was originally published on MedicalXpress.com
